A CAR enhancer increases the activity and persistence of CAR T cells.

Autor: Rakhshandehroo T; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Mantri SR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Moravej H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Louis BBV; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Salehi Farid A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Munaretto L; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Regan K; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Khan RMM; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Wolff A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Farkash Z; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Cong M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Kuhnast A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Nili A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee UJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Allen HH; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Berland L; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Simkova E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Uslu SC; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Tavakolpour S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Rowley JE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Codet E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Shahbazian H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Baral J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Pyrdol J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobson CA; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nadeem O; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nia HT; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Rashidian M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Mohammad_rashidian@dfci.harvard.edu.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2024 Jul 30. Date of Electronic Publication: 2024 Jul 30.